The potentially transformative effect of Daiichi Sankyo Co. Ltd.'s proposed rare cancer treatment pexidartinib trumped concerns about liver toxicity and the monitoring that may be required in advisory committee members' minds.
The US Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12-3 that the benefits of pexidartinib outweighed the risks during the morning session of its 14 May meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?